ConductScience.org, home

Comparison · NCT00772941-26bd6228

Varenicline - With Concomitant Therapies vs Varenicline - Without Concomitant Therapies: Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Therapies.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Varenicline - With Concomitant Therapies vs Varenicline - Without Concomitant Therapies: Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Therapies. Trial comparisons, record NCT00772941-26bd6228. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00772941-26bd6228

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.4460.3520.543wilson
Risk in group 20.2120.1980.226wilson
Risk difference, group 1 minus group 20.2340.140.332newcombe hybrid score
Risk ratio, group 1 over group 22.11.682.64log
Odds ratio, group 1 over group 22.9924.47log
Number needed to treat, for one more participant with the outcome on Varenicline - With Concomitant Therapies than on Varenicline - Without Concomitant Therapies4.283.017.16from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Varenicline - With Concomitant TherapiesParticipants receiving concomitant therapies while taking Varenicline according to Japanese Package Insert.45101OG000
Group 2Varenicline - Without Concomitant TherapiesParticipants receiving no concomitant therapies while taking Varenicline according to Japanese Package Insert.6683,156OG001

Outcome

Type
PRIMARY
Title
Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Therapies.
Description
Number of participants with Treatment Related Adverse Events of Varenicline to determine whether receiving concomitant therapies is a significant risk factor.
Time frame
24 weeks
Population
The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed.

Source ClinicalTrials.gov

Trial

Title
Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
NCT number
NCT00772941
Phases
Conditions
Smoking Cessation
Interventions
Varenicline
Lead sponsor
Pfizer
Results first posted
2014-01-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00772941-26bd6228